Last Updated : April 11, 2024
Details
FilesGeneric Name:
nirmatrelvir/ritonavir
Project Status:
Active
Therapeutic Area:
Mild-to-moderate COVID-19, treatment
Manufacturer:
Pfizer Canada ULC
Call for patient/clinician input open:
Brand Name:
Paxlovid
Project Line:
Reimbursement Review
Project Number:
SR0808-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | August 03, 2023 |
|---|---|
| Call for patient/clinician input closed | September 25, 2023 |
| Clarification: - Patient input submission received from the Gastrointestinal Society, Lung Health Foundation, Save Your Skin Foundation and Sickle Cell Awareness Group of Ontario | |
| Submission received | September 15, 2023 |
| Submission accepted | September 29, 2023 |
| Review initiated | October 03, 2023 |
| Draft CADTH review report(s) provided to sponsor for comment | November 07, 2023 |
| Deadline for sponsors comments | November 14, 2023 |
| CADTH review report(s) and responses to comments provided to sponsor | December 08, 2023 |
| Expert committee meeting (initial) | December 20, 2023 |
| Draft recommendation issued to sponsor | January 09, 2024 |
| Draft recommendation posted for stakeholder feedback | January 18, 2024 |
| End of feedback period | February 02, 2024 |
| Clarification: - Reconsideration: major revisions requested by sponsor | |
| Expert committee meeting | March 27, 2024 |
| Final recommendation issued to sponsor and drug plans | April 11, 2024 |
| Final recommendation posted | - |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | April 25, 2024 |
| CADTH review report(s) posted | - |
Files
Last Updated : April 11, 2024